EMA Authorised: Aspaveli (pegcetacoplan) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

The European Medicines Agency authorised Aspaveli (pegcetacoplan) by Swedish Orphan Biovitrum AB (publ) for the treatment of paroxysmal nocturnal hemoglobinuria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Aspaveli (pegcetacoplan)

Snippet

Status: Authorised. Therapeutic area: Hemoglobinuria, Paroxysmal. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 15/01/2026. Orphan medicine